Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 1.00 |
| ▸ | HPSE | Q9Y251 | 14/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.44 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.44 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7238051 | 0.89 | GAA (0.80) | GAAHPSEKDM4EMEN1ALDH1A1 | |
| SCHEMBL5733947 | 0.86 | GAA (0.75) | GAAHPSEKDM4EMEN1ALDH1A1 | |
| SCHEMBL3738502 | 0.85 | GAA (0.74) | GAAHPSEKDM4EMEN1ALDH1A1 | |
| SCHEMBL6790729 | 0.84 | GAA (0.72) | GAAHPSEKDM4EMEN1ALDH1A1 | |
| SCHEMBL11638476 | 0.83 | GAA (0.71) | GAAHPSEKDM4EMEN1ALDH1A1 | |
| SCHEMBL10224642 | 0.82 | GAA (0.69) | GAAKDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL3807350 | 0.82 | GAA (0.69) | GAAHPSEKDM4EMEN1ALDH1A1 | |
| SCHEMBL7472281 | 0.81 | GAA (0.68) | GAAKDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL506581 | 0.81 | GAA (0.67) | GAAHPSEKDM4EMEN1ALDH1A1 | |
| SCHEMBL7231101 | 0.79 | GAA (0.65) | GAAHPSEKDM4EMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100249176-A1 | HETEROCYCLE AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | BARROW JAMES C | 2010-09-30 | — | — | US | disclosed |
| EP-2212293-A1 | HETEROCYCLE AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009054983-A1 | HETEROCYCLE AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK & CO., INC. (US) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249176-A1 | HETEROCYCLE AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | CACNA1G, CACNA1H, CACNA1I | GAA 2264/4885HPSE 3928/4885KDM4E 3538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.